Orodispersible Levitra tablet launched for ED

Levitra is the first ED drug to be launched as an orodispersible formulation
Levitra is the first ED drug to be launched as an orodispersible formulation

Erectile dysfunction treatment vardenafil (Levitra) is now available as an orodispersible tablet.

Placed on the tongue approximately 60 minutes before sexual activity, the 10mg tablet rapidly dissolves without the need to take separate liquid.

Efficacy of the orodispersible tablet was demonstrated in two 12-week studies of identical design, POTENT I and POTENT II.

The 2 studies enrolled a total of 882 men who had had erectile dysfunction for more than 6 months. In both studies, the orodispersible tablets were significantly superior to placebo for all efficacy measures (p<0.0001 for all), both primary (International Index of Erectile Function and Sexual Encounter Profile questions 2 and 3) and secondary.

Levitra orodispersible tablets are not indicated for initiation of vardenafil treatment in patients with mild hepatic impairment.

View Levitra drug record

Further information: Bayer

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases